CMC Considerations for Developing an Effective mRNA/LNP Therapeutic

mRNA Development and Manufacturing - CMC Challenges and SolutionsПодробнее

Challenges and Considerations for mRNA Therapeutic DevelopmentПодробнее

A Q&A On CMC In mRNA ManufacturingПодробнее

Accelerate development by outsourcing MRNA–LNP formulations to a CDMOПодробнее

Science & serendipity: lipid nanoparticles that enable COVID-19 mRNA vaccines - Gairdner LecturesПодробнее

Clinical and Commercial Manufacturing of mRNA Therapeutics: Opportunities and ChallengesПодробнее

Translating mRNA-Based Medicines from Concept to ClinicПодробнее

CMC Considerations For mRNA ManufacturingПодробнее

Challenges for mRNA LNP Formulation Development and ManufacturingПодробнее

Developing Scalable RNA-LNP Drug Products for Clinical ReadinessПодробнее

The Scientific Underpinnings of mRNA/LNPsПодробнее

Process & Analytical Insights for GMP Manufacturing of mRNA-Lipid NanoparticlesПодробнее

Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA DeliveryПодробнее

Achieving mRNA-LNP Delivery Beyond the LiverПодробнее

Standardizing Scale-up: Insights into Producing Clinical and Commercial RNA-LNP Drug ProductsПодробнее

RNA-LNP Therapeutics Panel DiscussionПодробнее

Development of mRNA and its ApplicationsПодробнее

Enabling and advancing mRNA-LNP medicines from concept to clinic - CytivaПодробнее

Enabling and advancing mRNA-LNP medicines from concept to clinicПодробнее